查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571666

子宫颈癌治疗市场规模、份额、趋势分析报告：按类型、治疗方法、最终用途、地区和细分市场预测，2024-2030 年

Cervical Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment, By End-use (Hospital & Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

子宫颈癌治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球子宫颈癌治疗市场规模将达117.4亿美元，2024年至2030年复合年增长率为5.4%。

治疗渗透率的提高和疾病盛行率的上升预计将推动未来几年的市场成长。 HPV 主要透过性行为传播，但也可能由其他因素引起，例如口服避孕药、多重性伴侣、吸烟和 HIV 感染。 HPV有100多种株，其中13种是高危险或癌症的。鳞状细胞癌是最常见的，占所有病例的近85%。

鳞状细胞癌和腺癌的区分是基于显微镜下观察的组织学图像。子宫颈腺鳞癌很罕见，包含鳞状和腺组织的混合物。子宫颈癌的治疗方法大致分为预防和治疗。为了预防，有针对 HPV 的疫苗。目前市面上有两种疫苗： Gardasil和Cervarix。治疗选择包括Avastin等生物製药和拓扑替康、Cisplatin、博来霉素、Fluorouracil、紫杉醇、Carboplatin和阿霉素等学名药。开发具有提高疗效和降低成本的标靶治疗仍然是该市场中未满足的主要需求。然而，对包括子宫颈癌在内的肿瘤学研发的日益关注表明该市场的未来充满希望。

子宫颈癌治疗市场报告亮点

  • 鳞状细胞癌类型占市场主导地位，2023年占最大销售份额，为71.1%。这种增长是由于高风险人类乳突病毒 (HPV) 亚型（主要是 HPV 16 和 18）持续感染所致，这两种亚型占病例的大多数。
  • 化疗治疗引领市场，2023年占最大销售份额，达33.9%。这种增长归因于药物开发的进步，大大增加了子宫颈腺癌的治疗选择。
  • 医院和诊所细分市场占据主导地位，2023 年收益占有率最大，为 65.0%。这一增长归因于医院和诊所的分娩程序的加强，包括标靶治疗、放射线治疗、免疫疗法、微创手术和许多其他方法。
  • 北美子宫颈癌治疗市场主导全球市场，2023年占最大销售份额，达39.4%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章子宫颈癌治疗市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 子宫颈癌治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章子宫颈癌治疗市场：按类型估计和趋势分析

  • 细分仪表板
  • 子宫颈癌治疗市场波动分析：按类型，2023 年和 2030 年
  • 鳞状细胞癌
  • 腺癌
  • 腺鳞癌
  • 其他的

第五章子宫颈癌治疗市场：依治疗分类的估计与趋势分析

  • 细分仪表板
  • 子宫颈癌治疗市场波动分析：依治疗方式，2023 年和 2030 年
  • 放射治疗
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 其他的

第六章子宫颈癌治疗市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 子宫颈癌治疗市场波动分析：依最终用途分类，2023 年和 2030 年
  • 医院/诊所
  • 门诊手术中心
  • 其他的

第七章子宫颈癌治疗市场：依地区估算及趋势分析

  • 2023 年和 2030 年按地区分類的子宫颈癌治疗市场占有率
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Merck &Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Eli Lilly and Company.
    • Novartis AG
    • AstraZeneca
    • GSK plc.
    • AbbVie Inc.
    • Johnson &Johnson Services, Inc.
简介目录
Product Code: GVR-2-68038-718-6

Cervical Cancer Treatment Market Growth & Trends:

The global cervical cancer treatment market size is expected to reach USD 11.74 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increased treatment penetration and rising disease incidence are projected to drive the market growth over the next few years. Although, sexually transmitted HPV is a major cause, the disease can also be triggered by other factors, such as oral contraceptives, multiple sexual partners, smoking, and HIV infection. There are more than 100 strains of HPV, 13 of which are high-risk or cancerous. Squamous cell carcinoma is the most common type and it accounts for nearly 85% of the overall cases.

The differentiation between squamous cell carcinoma and adenocarcinoma is based on the histology, as observed under the microscope. Cervical adenosquamous carcinoma is rare, involving a mixture of squamous and glandular tissues. Products for cervical cancer can be broadly classified into prevention and treatment. Preventive options involve vaccines against HPV. Currently, there are two commercial vaccines - Gardasil and Cervarix. Treatment options include biologics, such as Avastin and generics like topotecan, cisplatin, bleomycin, fluorouracil, paclitaxel, carboplatin, and doxorubicin. The development of targeted therapeutics with improved efficacy and reduced cost remains a key unmet need of this market. Nevertheless, expanding focus on the research and development in oncology, including cervical cancer, indicate a promising future for this market.

Cervical Cancer Treatment Market Report Highlights:

  • Squamous cell carcinoma type dominated the market and accounted for the largest revenue share of 71.1% in 2023. This growth is attributed to persistent infection with high-risk human papillomavirus (HPV) subtypes, mainly HPV 16 and 18, which account for most cases.
  • Chemotherapy treatment led the market and accounted for the largest revenue share of 33.9% in 2023. This growth is attributed to the advancements in drug development that have significantly enhanced treatment options for cervical adenocarcinoma.
  • Hospitals & clinics segment dominated the market and accounted for the largest revenue share of 65.0% in 2023. This growth is attributed to the enhanced delivery procedures in hospitals & clinics with offerings such as targeted therapy, radiation therapy, immunotherapy, minimally invasive surgeries, and many other methods.
  • The North America cervical cancer treatment market dominated the global market and accounted for the largest revenue share of 39.4% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cervical Cancer Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cervical Cancer Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cervical Cancer Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cervical Cancer Treatment Market: Type Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Squamous Cell Carcinoma
    • 4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Adenocarcinoma
    • 4.4.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Adenosquamous Carcinoma
    • 4.5.1. Adenosquamous Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Types
    • 4.6.1. Other Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cervical Cancer Treatment Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cervical Cancer Treatment Market: Treatment Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Radiation Therapy
    • 5.3.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. External Beam Radiation Therapy (EBRT)
      • 5.3.2.1. External Beam Radiation Therapy (EBRT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Brachytherapy
      • 5.3.3.1. Brachytherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Cisplatin
      • 5.4.2.1. Cisplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Carboplatin
      • 5.4.3.1. Carboplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Paclitaxel
      • 5.4.4.1. Paclitaxel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. Other Chemotherapeutic Agents
      • 5.4.5.1. Other Chemotherapeutic Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Bevacizumab (Avastin)
      • 5.5.2.1. Bevacizumab (Avastin) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Other Targeted Therapies
      • 5.5.3.1. Other Targeted Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Pembrolizumab (Keytruda)
      • 5.6.2.1. Pembrolizumab (Keytruda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. Other Immune Checkpoint Inhibitors
      • 5.6.3.1. Other Immune Checkpoint Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other Therapies
    • 5.7.1. Other Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cervical Cancer Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cervical Cancer Treatment Market: End Use Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospitals & Clinics
    • 6.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Ambulatory Surgery Centers
    • 6.4.1. Ambulatory Surgery Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cervical Cancer Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Cervical Cancer Treatment Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Merck & Co., Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Bristol-Myers Squibb Company
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. F. Hoffmann-La Roche Ltd
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Pfizer Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Eli Lilly and Company.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. AstraZeneca
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. GSK plc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. AbbVie Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Johnson & Johnson Services, Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives